297 related articles for article (PubMed ID: 29594953)
1. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B
Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH
Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
4. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
[TBL] [Abstract][Full Text] [Related]
7. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
[TBL] [Abstract][Full Text] [Related]
11. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
13. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
14. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Álvarez Lerma F; Muñoz Bermudez R; Grau S; Gracia Arnillas MP; Sorli L; Recasens L; Mico García M
Rev Esp Quimioter; 2017 Jun; 30(3):224-228. PubMed ID: 28361526
[TBL] [Abstract][Full Text] [Related]
17. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
[TBL] [Abstract][Full Text] [Related]
18. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Munita JM; Aitken SL; Miller WR; Perez F; Rosa R; Shimose LA; Lichtenberger PN; Abbo LM; Jain R; Nigo M; Wanger A; Araos R; Tran TT; Adachi J; Rakita R; Shelburne S; Bonomo RA; Arias CA
Clin Infect Dis; 2017 Jul; 65(1):158-161. PubMed ID: 28329350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]